The role of dentists in controlling hepatocellular carcinoma in Japan (Review)

Nagao,Yumiko

doi:10.3892/etm.2020.9545

The role of dentists in controlling hepatocellular carcinoma in Japan (Review)

Authors:
- Yumiko Nagao
View Affiliations

Affiliations: Department of Public Health, Graduate School of Medicine, Juntendo University, Bunkyo‑ku, Tokyo 113‑8421, Japan
Published online on: December 3, 2020 https://doi.org/10.3892/etm.2020.9545
Article Number: 113
Copyright: © Nagao . This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In Japan, the method of treatment for hepatitis is well established due to the high rates of hepatitis C. However, the identification of patients with hepatitis who do not receive appropriate treatment poses a major problem. Some patients with this disease may need to consult with a dentist due to the development of extrahepatic manifestations, such as lichen planus, in the oral cavity. Alternatively, the dentist might discover patients with untreated hepatitis C and hepatitis B during routine dental examination. In such cases, the patient should be referred to a hepatologist for further examinations and treatment. Thus, dentists are required to act as ‘gatekeepers of hepatitis’. Furthermore, Japanese dentists need to increase hepatitis B vaccine coverage for infection control. By acting as a ‘care coordinator of hepatitis’, the dentist will be able to contribute to the eradication of liver cancer in Japan, thereby eliminating the discrimination and prejudice against patients with hepatitis. Dentists need to have a deep understanding of liver disease from the viewpoints of both nosocomial infection control and treatment of oral diseases.

View Figures

View References

1	WHO: Hepatitis B Fact sheet July 2019. urihttp://www.who.int/mediacentre/factsheets/fs204/en/simplehttp://www.who.int/mediacentre/factsheets/fs204/en/.
2	WHO: Hepatitis C Fact sheet July 2019. urihttp://www.who.int/mediacentre/factsheets/fs164/en/simplehttp://www.who.int/mediacentre/factsheets/fs164/en/.
3	WHO. Global Health Sector Strategies on Viral Hepatitis, 2016-2021. urihttp://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1simplehttp://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_32-en.pdf?ua=1.
4	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
5	Simonetti RG, Cammà C, Fiorello F, Cottone M, Rapicetta M, Marino L, Fiorentino G, Craxì A, Ciccaglione A, Giuseppetti R, et al: Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study. Ann Intern Med. 116:97–102. 1992.PubMed/NCBI View Article : Google Scholar
6	El-Serag HB: Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142:1264–1273.e1. 2012.PubMed/NCBI View Article : Google Scholar
7	Umemura T, Ichijo T, Yoshizawa K, Tanaka E and Kiyosawa K: Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 44 (Suppl 19):102–107. 2009.PubMed/NCBI View Article : Google Scholar
8	Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, et al: APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int. 10:681–701. 2016.PubMed/NCBI View Article : Google Scholar
9	Tanaka J, Akita T, Ohisa M, Sakamune K, Ko K, Uchida S and Satake M: Trends in the total numbers of HBV and HCV carriers in Japan from 2000 to 2011. J Viral Hepat. 25:363–372. 2018.PubMed/NCBI View Article : Google Scholar
10	Tanaka J, Akita T, Ko K, Miura Y and Satake M: Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view. Hepatol Res. 49:990–1002. 2019.PubMed/NCBI View Article : Google Scholar
11	Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology. Japan Society of Hepatology guidelines for the management of hepatitis C virus infection: 2019 update. Hepatol Res. 50:791–816. 2020.PubMed/NCBI View Article : Google Scholar
12	Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, Toyoda H, Yokosuka O, Nirei K, Genda T, et al: Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: An open-label, phase 3 trial. J Viral Hepat. 21:762–768. 2014.PubMed/NCBI View Article : Google Scholar
13	Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, et al: Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 59:2083–2091. 2014.PubMed/NCBI View Article : Google Scholar
14	Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, Nakane K, Enomoto H, Ikeda F, Yanase M, et al: Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: An open-label, randomised, phase 3 trial. Lancet Infect Dis. 15:645–653. 2015.PubMed/NCBI View Article : Google Scholar
15	Chayama K, Suzuki F, Karino Y, Kawakami Y, Sato K, Atarashi T, Naganuma A, Watanabe T, Eguchi Y, Yoshiji H, et al: Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis. J Gastroenterol. 53:557–565. 2018.PubMed/NCBI View Article : Google Scholar
16	Juanbeltz R, Pérez-García A, Aguinaga A, Martínez-Baz I, Casado I, Burgui C, Goñi-Esarte S, Repáraz J, Zozaya JM, San Miguel R, et al: Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. PLoS One. 13(e0208554)2018.PubMed/NCBI View Article : Google Scholar
17	Calvaruso V, Cabibbo G, Cacciola I, Petta S, Madonia S, Bellia A, Tinè F, Distefano M, Licata A, Giannitrapani L, et al: Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents. Gastroenterology. 155:411–421.e4. 2018.PubMed/NCBI View Article : Google Scholar
18	Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, et al: Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: A prospective cohort study. Lancet. 393:1453–1464. 2019.PubMed/NCBI View Article : Google Scholar
19	Razavi H, Sanchez Gonzalez Y, Yuen C and Cornberg M: Global timing of hepatitis C virus elimination in high-income countries. Liver Int. 40:522–529. 2020.PubMed/NCBI View Article : Google Scholar
20	Aghemo A, Lampertico P and Colombo M: Assessing long-term treatment efficacy in chronic hepatitis B and C: Between evidence and common sense. J Hepatol. 57:1326–1335. 2012.PubMed/NCBI View Article : Google Scholar
21	Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, et al: Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 351:1521–1531. 2004.PubMed/NCBI View Article : Google Scholar
22	Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, et al: A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 354:1001–1010. 2006.PubMed/NCBI View Article : Google Scholar
23	European Association for the Study of the Liver. Electronic address: simpleeasloffice@easloffice.eu; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 67:370–398. 2017.PubMed/NCBI View Article : Google Scholar
24	Tanaka J: Ministry of Health, Labor and Welfare 13th Council for Promotion of Measures against Hepatitis, 2015 (In Japanese) urihttps://http://www.mhlw.go.jp/stf/shingi2/0000075691.htmlsimplehttps://http://www.mhlw.go.jp/stf/shingi2/0000075691.html.
25	Tatsuoka S: Ministry of Health, Labor and Welfare, Research project for practical application of medical treatment in the field of diseases such as intractable diseases and cancer (hepatitis-related research field) (In Japanese).
26	Nagao Y, Kawahigashi Y, Kimura K, Nobayashi H and Sata M: Awareness survey of prejudice and discrimination in hepatitis B and C virus-infected individuals. Adv Res Gastroentero Hepatol. 7:6–11. 2017.
27	Ministry of Health, Labor and Welfare, Study meeting for improving the quality of dentist 2017 (In Japanese) urihttps://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000165542.pdfsimplehttps://http://www.mhlw.go.jp/file/05-Shingikai-10801000-Iseikyoku-Soumuka/0000165542.pdf.
28	Yatsuhashi H: Past, present, and future of viral hepatitis C in Japan. Euroasian J Hepatogastroenterol. 6:49–51. 2016.PubMed/NCBI View Article : Google Scholar
29	Toyoda H, Kumada T, Takaguchi K, Shimada N and Tanaka J: Changes in hepatitis C virus genotype distribution in Japan. Epidemiol Infect. 142:2624–2628. 2014.PubMed/NCBI View Article : Google Scholar
30	Kobayashi K: Questionnaire study of needlestick injures and hepatitis B vaccination in general dental practices. Japanese J Environmental Inf. 30:348–353. 2015.(In Japanese).
31	Olubuyide IO, Ola SO, Aliyu B, Dosumu OO, Arotiba JT, Olaleye OA, Odaibo GN, Odemuyiwa SO and Olawuyi F: Hepatitis B and C in doctors and dentists in Nigeria. QJM. 90:417–422. 1997.PubMed/NCBI View Article : Google Scholar
32	Nagao Y, Matsuoka H, Kawaguchi T, Ide T and Sata M: HBV and HCV infection in Japanese dental care workers. Int J Mol Med. 21:791–799. 2008.PubMed/NCBI
33	Nagao Y, Ozaki T, Kawaguchi A, Chiba I, Harada K, Saito T and Shiratsuchi S: Survey of dental health care workers regarding their knowledge of viral liver disease and prevention of its transmission, using an online questionnaire. Adv Res Gastroentero Hepatol. 10:95–108. 2018.
34	Ali A, Khan S, Malik SM, Haris Iqbal M and Aadil M: Comparison of knowledge and attitudes regarding hepatitis B among healthcare professionals in Pakistan. Cureus. 9(e1049)2017.PubMed/NCBI View Article : Google Scholar
35	Garus-Pakowska A, Górajski M and Szatko F: Knowledge and attitudes of dentists with respect to the risks of blood-borne pathogens-A cross-sectional study in Poland. Int J Environ Res Public Health. 14(69)2017.PubMed/NCBI View Article : Google Scholar
36	Gambhir RS, Kumar M, Singh G, Singh A and Kaur A: Hepatitis C: Knowledge and awareness of private dental practitioners of a tricity in India. J Educ Health Promot. 7(7)2018.PubMed/NCBI View Article : Google Scholar
37	Rostamzadeh M, Afkhamzadeh A, Afrooz S, Mohamadi K and Rasouli MA: Dentists' knowledge, attitudes and practices regarding Hepatitis B and C and HIV/AIDS in Sanandaj, Iran. BMC Oral Health. 18(220)2018.PubMed/NCBI View Article : Google Scholar
38	Nagao Y, Kawaguchi T, Ide T and Sata M: HCV or HBV infection self-disclosure to dentists. Kansenshogaku Zasshi. 82:213–219. 2008.PubMed/NCBI View Article : Google Scholar : (In Japanese).
39	Medina JB, Andrade NS, de Paula Eduardo F, Bezinelli L, Franco JB, Gallottini M, Braz-Silva PH and Ortega KL: Bleeding during and after dental extractions in patients with liver cirrhosis. Int J Oral Maxillofac Surg. 47:1543–1549. 2018.PubMed/NCBI View Article : Google Scholar
40	Glassman P, Wong C and Gish R: A review of liver transplantation for the dentist and guidelines for dental management. Spec Care Dentist. 13:74–80. 1993.PubMed/NCBI View Article : Google Scholar
41	Brigo S, Mancuso E and Pellicano R: Dentistry and oral and maxillofacial surgery in the patient with liver disease: Key messages for clinical practice. Minerva Stomatol. 68:192–199. 2019.PubMed/NCBI View Article : Google Scholar
42	Andreasen JO: Oral lichen planus. 1. A clinical evaluation of 115 cases. Oral Surg Oral Med Oral Pathol. 25:31–42. 1968.PubMed/NCBI View Article : Google Scholar
43	Pawlotsky JM, Ben Yahia M, Andre C, Voisin MC, Intrator L, Roudot-Thoraval F, Deforges L, Duvoux C, Zafrani ES, Duval J, et al: Immunological disorders in C virus chronic active hepatitis: A prospective case-control study. Hepatology. 19:841–848. 1994.PubMed/NCBI
44	El-Serag HB, Hampel H, Yeh C and Rabeneck L: Extrahepatic manifestations of hepatitis C among United States male veterans. Hepatology. 36:1439–1445. 2002.PubMed/NCBI View Article : Google Scholar
45	Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ and Manns MP: Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 149:1345–1360. 2015.PubMed/NCBI View Article : Google Scholar
46	Ferri C, Ramos-Casals M, Zignego AL, Arcaini L, Roccatello D, Antonelli A, Saadoun D, Desbois AC, Sebastiani M, Casato M, et al: International diagnostic guidelines for patients with HCV-related extrahepatic manifestations. A multidisciplinary expert statement. Autoimmun Rev. 15:1145–1160. 2016.PubMed/NCBI View Article : Google Scholar
47	Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC and Opolon P: Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 42:2204–2212. 1999.PubMed/NCBI View Article : Google Scholar
48	Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, et al: Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Groupe d'Etude et de Recherche en Medecine Interne et Maladies Infectieuses sur le Virus de l'Hepatite C. Medicine (Baltimore). 79:47–56. 2000.PubMed/NCBI View Article : Google Scholar
49	Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, Mihailova AP, Hadjiev EA, Dikova RP, Vukov MI and Tchernev KG: Chronic hepatitis C virus infection: Prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol. 13:6518–6528. 2007.PubMed/NCBI View Article : Google Scholar
50	Nagao Y, Sata M, Tanikawa K, Itoh K and Kameyama T: Lichen planus and hepatitis C virus in the northern Kyushu region of Japan. Eur J Clin Invest. 25:910–914. 1995.PubMed/NCBI View Article : Google Scholar
51	Carrozzo M, Gandolfo S, Carbone M, Colombatto P, Broccoletti R, Garzino-Demo P and Ghisetti V: Hepatitis C virus infection in Italian patients with oral lichen planus: A prospective case-control study. J Oral Pathol Med. 25:527–533. 1996.PubMed/NCBI View Article : Google Scholar
52	Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mal F, Callard P and Beaugrand M: Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease. Lancet. 339:321–323. 1992.PubMed/NCBI View Article : Google Scholar
53	Koike K, Moriya K, Ishibashi K, Yotsuyanagi H, Shintani Y, Fujie H, Kurokawa K, Matsuura Y and Miyamura T: Sialadenitis histologically resembling Sjögren syndrome in mice transgenic for hepatitis C virus envelope genes. Proc Natl Acad Sci USA. 94:233–236. 1997.PubMed/NCBI View Article : Google Scholar
54	Nagao Y, Hanada S, Shishido S, Ide T, Kumashiro R, Ueno T and Sata M: Incidence of Sjögren's syndrome in Japanese patients with hepatitis C virus infection. J Gastroenterol Hepatol. 18:258–266. 2003.PubMed/NCBI View Article : Google Scholar
55	Nagao Y, Sata M, Tanikawa K, Itoh K and Kameyama T: High prevalence of hepatitis C virus antibody and RNA in patients with oral cancer. J Oral Pathol Med. 24:354–360. 1995.PubMed/NCBI View Article : Google Scholar
56	Mahale P, Sturgis EM, Tweardy DJ, Ariza-Heredia EJ and Torres HA: Association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst. 108(djw035)2016.PubMed/NCBI View Article : Google Scholar
57	Nagao Y and Sata M: Hepatitis C virus and lichen planus. J Gastroenterol Hepatol. 19:1101–1113. 2004.PubMed/NCBI View Article : Google Scholar
58	Carrozzo M: Oral diseases associated with hepatitis C virus infection. Part 2: Lichen planus and other diseases. Oral Dis. 14:217–228. 2008.PubMed/NCBI View Article : Google Scholar
59	Shengyuan L, Songpo Y, Wen W, Wenjing T, Haitao Z and Binyou W: Hepatitis C virus and lichen planus: A reciprocal association determined by a meta-analysis. Arch Dermatol. 145:1040–1047. 2009.PubMed/NCBI View Article : Google Scholar
60	Lodi G, Pellicano R and Carrozzo M: Hepatitis C virus infection and lichen planus: A systematic review with meta-analysis. Oral Dis. 16:601–612. 2010.PubMed/NCBI View Article : Google Scholar
61	Petti S, Rabiei M, De Luca M and Scully C: The magnitude of the association between hepatitis C virus infection and oral lichen planus: Meta-analysis and case control study. Odontology. 99:168–178. 2011.PubMed/NCBI View Article : Google Scholar
62	Alaizari NA, Al-Maweri SA, Al-Shamiri HM, Tarakji B and Shugaa-Addin B: Hepatitis C virus infections in oral lichen planus: A systematic review and meta-analysis. Aust Dent J. 61:282–287. 2016.PubMed/NCBI View Article : Google Scholar
63	Gandolfo S, Richiardi L, Carrozzo M, Broccoletti R, Carbone M, Pagano M, Vestita C, Rosso S and Merletti F: Risk of oral squamous cell carcinoma in 402 patients with oral lichen planus: A follow-up study in an Italian population. Oral Oncol. 40:77–83. 2004.PubMed/NCBI View Article : Google Scholar
64	Nagao Y, Sata M, Suzuki H, Kameyama T and Ueno T: Histological improvement of oral lichen planus in patients with chronic hepatitis C treated with interferon. Gastroenterology. 117:283–284. 1999.PubMed/NCBI View Article : Google Scholar
65	Núñez M, Miralles ES, de las Heras ME and Ledo A: Appearance of oral erosive lichen planus during interferon alfa-2a therapy for chronic active hepatitis C. J Dermatol. 22:461–462. 1995.PubMed/NCBI View Article : Google Scholar
66	Nagao Y, Sata M, Ide T, Suzuki H, Tanikawa K, Itoh K and Kameyama T: Development and exacerbation of oral lichen planus during and after interferon therapy for hepatitis C. Eur J Clin Invest. 26:1171–1174. 1996.PubMed/NCBI View Article : Google Scholar
67	Varela P, Areias J, Mota F, Canelhas A and Sanches M: Oral lichen planus induced by interferon-alpha-N1 in a patient with hepatitis C. Int J Dermatol. 39:239–240. 2000.PubMed/NCBI View Article : Google Scholar
68	Areias J, Velho GC, Cerqueira R, Barbêdo C, Amaral B, Sanches M, Massa A and Saraiva AM: Lichen planus and chronic hepatitis C: Exacerbation of the lichen under interferon-alpha-2a therapy. Eur J Gastroenterol Hepatol. 8:825–828. 1996.PubMed/NCBI
69	Nagao Y, Kawaguchi T, Ide T, Kumashiro R and Sata M: Exacerbation of oral erosive lichen planus by combination of interferon and ribavirin therapy for chronic hepatitis C. Int J Mol Med. 15:237–241. 2005.PubMed/NCBI
70	Nagao Y, Kimura K, Kawahigashi Y and Sata M: Successful treatment of hepatitis C virus-associated oral lichen planus by interferon-free therapy with direct-acting antivirals. Clin Transl Gastroenterol. 7(e179)2016.PubMed/NCBI View Article : Google Scholar
71	Misaka K, Kishimoto T, Kawahigashi Y, Sata M and Nagao Y: Use of direct-acting antivirals for the treatment of hepatitis C virus-associated oral lichen planus: A case report. Case Rep Gastroenterol. 10:617–622. 2016.PubMed/NCBI View Article : Google Scholar
72	Nagao Y, Nakasone K, Maeshiro T, Nishida N, Kimura K, Kawahigashi Y, Tanaka Y and Sata M: Successful treatment of oral lichen planus with direct-acting antiviral agents after liver transplantation for hepatitis C virus-associated hepatocellular carcinoma. Case Rep Gastroenterol. 11:701–710. 2017.PubMed/NCBI View Article : Google Scholar
73	Yoshikawa A, Terashita K, Morikawa K, Matsuda S, Yamamura T, Sarashina K, Nakano S, Kobayashi Y, Sogabe S, Takahashi K, et al: Interferon-free therapy with sofosbuvir plus ribavirin for successful treatment of genotype 2 hepatitis C virus with lichen planus: A case report. Clin J Gastroenterol. 10:270–273. 2017.PubMed/NCBI View Article : Google Scholar
74	Nagao Y and Tsuji M: The discovery through dentistry of potentially HCV-infected Japanese patients and intervention with treatment. Adv Res Gastroentero Hepatol. 7:38–44. 2017.
75	Harada K, Nakashima D, Nagao Y, Hidaka I, Sakaida I and Mishima K: Treatment of refractory oral lichen planus using direct antiviral agents in a patient with chronic hepatitis C: A case report. Oral Sci Int. 17:213–217. 2020.
76	Su TH, Tseng TC, Liu CJ, Chou SW, Liu CH, Yang HC, Chen PJ, Chen DS, Chen CL and Kao JH: Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer. Int J Cancer. 147:901–908. 2020.PubMed/NCBI View Article : Google Scholar
77	Cacoub P, Desbois AC, Comarmond C and Saadoun D: Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: A meta-analysis. Gut. 67:2025–2034. 2018.PubMed/NCBI View Article : Google Scholar
78	El-Serag HB, Christie IC, Puenpatom A, Castillo D, Kanwal F and Kramer JR: The effects of sustained virological response to direct-acting anti-viral therapy on the risk of extrahepatic manifestations of hepatitis C infection. Aliment Pharmacol Ther. 49:1442–1447. 2019.PubMed/NCBI View Article : Google Scholar
79	Nagao Y, Kameyama T and Sata M: Hepatitis C virus RNA detection in oral lichen planus tissue. Am J Gastroenterol. 93(850)1998.PubMed/NCBI View Article : Google Scholar
80	Nagao Y, Sata M, Noguchi S, Seno'o T, Kinoshita M, Kameyama T and Ueno T: Detection of hepatitis C virus RNA in oral lichen planus and oral cancer tissues. J Oral Pathol Med. 29:259–266. 2000.PubMed/NCBI View Article : Google Scholar
81	Arrieta JJ, Rodriguez-Inigo E, Casqueiro M, Bartolomé J, Manzarbeitia F, Herrero M, Pardo M and Carreno V: Detection of hepatitis C virus replication by In situ hybridization in epithelial cells of anti-hepatitis C virus-positive patients with and without oral lichen planus. Hepatology. 32:97–103. 2000.PubMed/NCBI View Article : Google Scholar
82	Nagao Y, Sata M, Itoh K, Tanikawa K and Kameyama T: Quantitative analysis of HCV RNA and genotype in patients with chronic hepatitis C accompanied by oral lichen planus. Eur J Clin Invest. 26:495–498. 1996.PubMed/NCBI View Article : Google Scholar
83	Lodi G, Carrozzo M, Hallett R, D'Amico E, Piattelli A, Teo CG, Gandolfo S, Carbone M and Porter SR: HCV genotypes in Italian patients with HCV-related oral lichen planus. J Oral Pathol Med. 26:381–384. 1997.PubMed/NCBI View Article : Google Scholar
84	Sánchez-Pérez J, Moreno-Otero R, Borque MJ, Rios-Buceta L and García-Díez A: Lichen planus and hepatitis C virus infection: A clinical and virologic study. Acta Derm Venereol. 78:305–306. 1998.PubMed/NCBI View Article : Google Scholar
85	Nagao Y and Sata M: A retrospective case-control study of hepatitis C virus infection and oral lichen planus in Japan: Association study with mutations in the core and NS5A region of hepatitis C virus. BMC Gastroenterol. 12(31)2012.PubMed/NCBI View Article : Google Scholar
86	Nagao Y, Nishida N, Toyo-Oka L, Kawaguchi A, Amoroso A, Carrozzo M, Sata M, Mizokami M, Tokunaga K and Tanaka Y: Genome-wide association study identifies risk variants for lichen planus in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol. 15:937–944.e5. 2017.PubMed/NCBI View Article : Google Scholar
87	Kaishima T, Fujii T, Matsuoka T, Sakamune K, Nagashima S, Yamamoto C, Chuon C, et al: Study of the issues of receiving hepatitis screening and the rate of consulting hospitals-The rate of recognized receiving hepatitis screening and that of the unrecognized. Kanzo. 57:634–648. 2016.(In Japanese).
88	Nagao Y, Sasaki T, Kuzuyama T, Takasato T, Yoshikawa S, Konishi H, Oka K, Yamaguchi T, Konishi Y, Hanada H, et al: Promotion by dentists of treatment of undiagnosed and untreated HCV-infected patients. Adv Res Gastroentero Hepatol. 9:86–90. 2018.
89	Nagao Y, Nishioka S and Koresawa K: Prevalence of viral liver disease and oral lichen planus in patients who visited dental clinics: A study by the Ehime Dental Association. OBM Hepatology Gastroenterology. 3:1–10. 2019.